Analysis of Prognostic Factors and the Role of Epilepsy in Neurosurgical Patients with Brain Metastases

Overview

Journal Surg Neurol Int

Specialty Neurology

Date 2024 Apr 17

PMID 38628515

Authors

Matteo Maria Ottaviani

Maria Rossella Fasinella

Alessandro Di Rienzo

Maurizio Gladi

Lucia Giovanna Maria di Somma

Maurizio Iacoangeli

Mauro Dobran

Affiliations

Soon will be listed here.

Abstract

Background: Brain metastases (BMs) represent the most frequent brain tumors in adults. The identification of key prognostic factors is essential for choosing the therapeutic strategy tailored to each patient. Epilepsy can precede several months of other clinical presentations of BMs. This work aimed to study the impact of epilepsy and other prognostic factors on BMs patients' survival.

Methods: This retrospective study included 51 patients diagnosed with BMs and who underwent neurosurgery between 2010 and 2021. The impact of BM features and patient's clinical characteristics on the overall survival (OS) was analyzed through uni- and multivariate analysis.

Results: The average OS was 25.98 months and differed according to the histology of the primary tumor. The primary tumor localization and the presence of extracranial metastases had a statistically significant impact on the OS, and patients with single BM showed a superior OS to those with multifocal lesions. The localization of BMs in the temporal lobe correlated with the highest OS. The OS was significantly higher in patients who presented seizures in their clinical onset and in those who had better post-surgical Karnofsky performance status, no post-surgical complications, and who underwent post-surgical treatment.

Conclusion: Our study has highlighted prognostically favorable patient and tumor factors. Among those, a clinical onset with epileptic seizures can help identify brain metastasis hitherto silent. This could lead to immediate diagnostic-therapeutic interventions with more aggressive therapies after appropriate multidisciplinary evaluation.

References

Kotecha R, Miller J, Venur V, Mohammadi A, Chao S, Suh J . Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. J Neurosurg. 2017; 129(1):50-59. DOI: 10.3171/2017.1.JNS162797. View

Venur V, Ahluwalia M . Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chin Clin Oncol. 2015; 4(2):18. DOI: 10.3978/j.issn.2304-3865.2015.06.01. View

Stankiewicz M, Tomasik B, Blamek S . A new prognostic score for predicting survival in patients treated with robotic stereotactic radiotherapy for brain metastases. Sci Rep. 2021; 11(1):20347. PMC: 8514560. DOI: 10.1038/s41598-021-98847-3. View

Kim Y, Lee E, Lee K . Clinical Analysis for Brain Tumor-Related Epilepsy during Chemotherapy for Systemic Cancer with Single Brain Metastasis. Cancer Res Treat. 2011; 43(3):160-9. PMC: 3192877. DOI: 10.4143/crt.2011.43.3.160. View

Soffietti R, Abacioglu U, Baumert B, Combs S, Kinhult S, Kros J . Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017; 19(2):162-174. PMC: 5620494. DOI: 10.1093/neuonc/now241. View

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

Sperduto P, Jiang W, Brown P, Braunstein S, Sneed P, Wattson D . The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2017; 98(5):1069-1077. PMC: 6925531. DOI: 10.1016/j.ijrobp.2017.03.030. View

Chan V, Sahgal A, Egeto P, Schweizer T, Das S . Incidence of seizure in adult patients with intracranial metastatic disease. J Neurooncol. 2016; 131(3):619-624. DOI: 10.1007/s11060-016-2335-2. View

10.

Sperduto P, Yang T, Beal K, Pan H, Brown P, Bangdiwala A . The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. Int J Radiat Oncol Biol Phys. 2016; 96(2):406-413. PMC: 5575932. DOI: 10.1016/j.ijrobp.2016.06.006. View

11.

Gaspar L, Scott C, Murray K, Curran W . Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000; 47(4):1001-6. DOI: 10.1016/s0360-3016(00)00547-2. View

12.

Miller J, Kotecha R, Ahluwalia M, Mohammadi A, Chao S, Barnett G . Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer. 2017; 123(12):2283-2293. DOI: 10.1002/cncr.30616. View

13.

Lassman A, DeAngelis L . Brain metastases. Neurol Clin. 2003; 21(1):1-23, vii. DOI: 10.1016/s0733-8619(02)00035-x. View

14.

Vecht C, Haaxma-Reiche H, Noordijk E, Padberg G, Voormolen J, Hoekstra F . Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol. 1993; 33(6):583-90. DOI: 10.1002/ana.410330605. View

15.

Kavouridis V, Harary M, Hulsbergen A, Lo Y, Reardon D, Aizer A . Survival and prognostic factors in surgically treated brain metastases. J Neurooncol. 2019; 143(2):359-367. DOI: 10.1007/s11060-019-03171-6. View

16.

Vecht C, Kerkhof M, Duran-Pena A . Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist. 2014; 19(7):751-9. PMC: 4077452. DOI: 10.1634/theoncologist.2014-0060. View

17.

Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R . A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8):494-500. DOI: 10.1056/NEJM199002223220802. View

18.

Winther R, Vik-Mo E, Yri O, Aass N, Kaasa S, Skovlund E . Surgery for brain metastases - real-world prognostic factors' association with survival. Acta Oncol. 2021; 60(9):1161-1168. DOI: 10.1080/0284186X.2021.1930150. View

19.

Ricciardi S, de Marinis F . Multimodality management of non-small cell lung cancer patients with brain metastases. Curr Opin Oncol. 2009; 22(2):86-93. DOI: 10.1097/CCO.0b013e3283350106. View

20.

Garcia J, Morshed R, Chung J, Millares Chavez M, Sudhakar V, Saggi S . Factors associated with preoperative and postoperative seizures in patients undergoing resection of brain metastases. J Neurosurg. 2022; 138(1):19-26. DOI: 10.3171/2022.3.JNS212285. View